InstalabLupus Anticoagulant Evaluation
Should you take a Lupus Anticoagulant Evaluation test?
This test is most useful if any of these apply to you.
3 biomarkers included
- PTT-LA ScreenA clotting test tuned to be sensitive to the antibody. It examines one branch of your clotting system and flags inhibitors a standard clotting test would miss.Why it mattersA prolonged result that does not correct with normal plasma points to an antibody inhibitor rather than a clotting-factor shortage.
- dRVVT ScreenThe dilute Russell viper venom time starts clotting further downstream, making it more specific for lupus anticoagulant and less thrown off by unrelated clotting-factor problems.Why it mattersA raised screen result that normalizes when extra phospholipid is added is the clearest single signal of the antibody.
- Lupus AnticoagulantThe combined verdict. It integrates both clotting tests through screen, mixing, and confirmation steps to report whether a true antibody inhibitor that depends on phospholipid is present.Why it mattersA positive result flags higher clotting and pregnancy risk and must be repeated after 12 weeks to confirm it is persistent.
About Lupus Anticoagulant Evaluation
Some people carry a quiet tendency to form dangerous blood clots, and nothing about a routine checkup reveals it. This panel hunts for one specific, well-studied cause: an immune antibody that makes your blood clot more easily in your body even though it makes a lab test clot more slowly.
That antibody, called lupus anticoagulant, is the single strongest laboratory predictor of clots and pregnancy problems in antiphospholipid syndrome (a clotting disorder driven by the immune system). Finding it changes how aggressively future clots are prevented.
What This Panel Reveals
The name is a historical misnomer. In a test tube the antibody slows clotting, but in your body it does the opposite and pushes clotting risk up. Because no single clotting test catches every version of this antibody, the panel deliberately uses two.
The two screens view clotting from different angles. The PTT-LA screen, a clotting test tuned to be sensitive to the antibody, examines one branch of your clotting system. The dRVVT screen (dilute Russell viper venom time, named for the snake venom that starts the reaction) triggers clotting further downstream and is more specific. Antibodies that show up on only one of the two are common, so running both catches cases a single test would miss.
The third line, the Lupus Anticoagulant result, is the interpretation. Rather than one number, the lab runs a screen, a mixing study, and a confirmation step, then reports whether a true phospholipid-dependent inhibitor (an antibody that targets the fats clotting depends on) is present.
How to Read Your Results Together
The logic follows three questions. Is a clotting time prolonged? Does it stay prolonged when your plasma is mixed with normal plasma, which points to an inhibitor rather than a missing clotting factor? And does it correct when extra phospholipid is added, which proves the inhibitor targets phospholipid? Only a yes to all three confirms lupus anticoagulant.
| Pattern | What It Suggests |
|---|---|
| Both screens normal | Lupus anticoagulant unlikely. Two normal tests are more reassuring than one. |
| Positive on dRVVT or PTT-LA but not both | Still counts as positive. Antibodies that react on only one assay are common. |
| Prolonged but corrects fully with normal plasma | Points to a clotting-factor shortage, not an antibody inhibitor. |
| Confirmed positive and still positive after 12 weeks | Persistent lupus anticoagulant, the highest-risk pattern. |
What to Do with Your Results
A positive result is a starting point, not a diagnosis. Antiphospholipid syndrome requires both a positive antibody and a clinical event such as a clot or a specific pregnancy complication, plus a repeat positive at least 12 weeks later to prove the antibody is persistent rather than a passing reaction to infection.
Pair this panel with the two antibody tests that measure the proteins directly, anticardiolipin and anti-beta-2-glycoprotein I. People positive on all three, called triple positive, carry the greatest risk. The size of that risk is meaningful: lupus anticoagulant has been linked to an odds ratio of 6.14 for vein clots and 3.58 for artery clots. In pregnancy it tracks with higher rates of preeclampsia (odds ratio 2.10), a small-for-gestational-age baby (odds ratio 1.78), and preterm birth (odds ratio 3.56).
If you are positive, a hematologist or rheumatologist should guide next steps and any decisions about blood thinners. This is a targeted panel, most useful for people who already have a clotting or pregnancy history rather than as a routine screen.
When Results Can Be Misleading
This whole panel is sensitive to blood thinners. Direct-acting oral anticoagulants and warfarin can create false positives or false negatives across both clotting tests, and heparin interferes as well. Testing is best done off anticoagulation when it is safe to do so, or timed and interpreted carefully with the lab.
Acute illness also distorts results. Infection and inflammation can push a clotting test positive temporarily, which is exactly why one positive result never stands alone and the repeat after 12 weeks is required.